Zhijuan Lin

Zhijuan Lin

Auto-generated profile, based on publicly available information

Zhijuan Lin

Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, 361003, China; Key laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancies, Xiamen, 361003, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
YZYining Zhang
Yining Zhang
YHYuqing Huang
Yuqing Huang
YHYan Hong
Yan Hong
ZLZhijuan Lin
Zhijuan Lin
JZJie Zha
Jie Zha
BXBing Xu
Bing Xu

6 January 2022 in Blood
Verified
Journal Article
Closed access
PDF file
QWQiang Wang
Qiang Wang
ZLZhijuan Lin
Zhijuan Lin
ZWZhuo Wang
Zhuo Wang
LYLingqun Ye
Lingqun Ye
MXMiao Xian
Miao Xian
QYQing Yi
Qing Yi
Proteasome inhibitors (PIs) such as bortezomib (Btz) and carfilzomib (Cfz) are highly efficacious for patients with multiple myeloma (MM). However, relapses are frequent, and acquired resistance to PI treatment emerges in most patients. Here, we performed a high-throughput screen of 1855 Food and Drug Administration (FDA)-approved drugs and identified all-trans retinoic acid (ATRA), which alone has no antimyeloma effect, as a potent drug that enhanced MM sensitivity to Cfz-induced cytotoxicity and resensitized Cfz-resistant MM cells to Cfz in vitro. ATRA activated retinoic acid receptor (RAR)γ and interferon-β response pathway, leading to upregulated expression of IRF1. IRF1 in turn initiated the transcription of OAS1, which synthesized 2-5A upon binding to double-stranded RNA (dsRNA) induced by Cfz and resulted in cellular RNA degradation by RNase L and cell death. Similar to ATRA, BMS961, a selective RARγ agonist, could also (re)sensitize MM cells to Cfz in vitro, and both ATRA and BMS961 significantly enhanced the therapeutic effects of Cfz in established MM in vivo. In support of these findings, analyses of large datasets of patients’ gene profiling showed a strong and positive correlation between RARγ and OAS1 expression and patient’s response to PI treatment. Thus, this study highlights the potential for RARγ agonists to sensitize and overcome MM resistance to Cfz treatment in patients.

29 December 2021
Verified
Report
Closed access
THThe First Affiliated Hospital Of Xiamen Hospital
The First Affiliated Hospital Of Xiamen Hospital
ZLZhijuan Lin
Zhijuan Lin
XCXing Chen
Xing Chen
LLLong Liu
Long Liu
HZHanyan Zeng
Hanyan Zeng
BXBing Xu
Bing Xu
INPLASY2021120131 The role of Central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: a network meta-analysis Keywords: central nervous system (CNS) relapses; diffus…

30 November 2021
Verified
Report
Closed access
THThe First Affiliated Hospital Of Xiamen Hospital
The First Affiliated Hospital Of Xiamen Hospital
ZLZhijuan Lin
Zhijuan Lin
XCXing Chen
Xing Chen
LLLong Liu
Long Liu
ZLZhifeng Li
Zhifeng Li
BXBing Xu
Bing Xu
Review question / Objective: FL is the most common indolent B cell lymphoma worldwide and patients with FL always have long term survival. However, advanced FL remains incurable and there is no universal agreement on optimal regimen to manage relapsed FL. Condition being studied: The efficacy of chemo-free regimens, including CD20 antibodies and targeted agents, in relapsed and/or refractory Follicular lymphoma. Information sources: We used the MEDLINE, Embase, and Cochrane Library databases to search the RCTs met our selection criteria. We also searched clinicalTrials.gov and the international clinical trial registry platform for completed and ongoing trials. In addition, we searched abstracts that published on American Society of Hematology (ASH), The European Hematology Association (EHA) or American Society of Clinical Oncology (ASCO) meetings.

1 October 2021 in Current Problems in Cancer
Verified
Journal Article
Closed access
ZLZhijuan Lin
Zhijuan Lin
XCXing Chen
Xing Chen
YHYueting Huang
Yueting Huang
HZHaijun Zhao
Haijun Zhao
ZLZhifeng Li
Zhifeng Li
BXBing Xu
Bing Xu